Pathophysiology of Polymyalgia Rheumatica
Polymyalgia rheumatica is driven by a complex interplay of age-related immune dysregulation, innate and adaptive immune system activation, and local inflammatory cytokine production in symptomatic muscles and periarticular structures.
Genetic and Immunogenetic Factors
The disease shows strong genetic associations, particularly with HLA-DRB1 alleles, suggesting genetic predisposition plays a foundational role 1. Additional immunogenetic links involve proinflammatory interleukins, particularly IL-6, which appears central to disease pathophysiology 1.
Age-Related Immune Alterations
Age is a critical pathophysiologic element, as PMR occurs exclusively in individuals over 50 years 1, 2, 3. Aging contributes through:
- Increased susceptibility to infections (potential disease triggers)
- Immunological modifications affecting immune cell function
- Hormonal disturbances that alter immune homeostasis 1
These age-related changes in genetically predisposed individuals likely create the permissive environment for disease development 4.
Immune System Activation
Innate Immunity
The innate immune system shows marked activation with:
- Dendritic cell activation
- Monocyte/macrophage activation driving IL-6 secretion 4
- This innate activation appears to be a primary driver of the systemic inflammatory response
Adaptive Immunity
Multiple adaptive immune disturbances characterize PMR:
- Decreased CD8+ T cells (a longstanding observation) 1
- Altered Th17/Treg cell balance, with dysregulation favoring inflammation 4
- Disturbed B cell homeostasis and function, indicating pathogenesis is more complex than previously understood 1, 4
Local Inflammatory Mechanisms
A groundbreaking finding demonstrates that symptomatic muscles themselves are sites of active inflammation 5. Microdialysis studies revealed:
- Markedly elevated interstitial concentrations of inflammatory cytokines (IL-1α/β, IL-6, IL-8, TNFα, MCP-1) in symptomatic vastus lateralis and trapezius muscles
- Interstitial cytokine levels exceeded plasma levels for most cytokines, indicating local production rather than systemic spillover
- These elevated levels normalized with prednisolone treatment, correlating with symptom resolution 5
This challenges the traditional view that symptoms arise solely from synovial inflammation and establishes muscle tissue as an active inflammatory site.
Structural Pathology
The disease involves:
- Synovial and periarticular inflammation around shoulder and pelvic girdle joints
- Muscular vasculopathy affecting blood vessels within symptomatic muscles 2
- Cellular infiltration around joints (though this remains incompletely characterized) 1
Systemic Inflammatory Response
IL-6 plays a central pathophysiologic role, driving:
- Systemic symptoms (fatigue, fever, weight loss) 2
- Acute phase response with elevated ESR and CRP
- The dramatic clinical response to IL-6 receptor blockade validates its centrality 6
Infectious Triggers
Multiple infectious agents have been investigated as potential triggers, though results remain inconclusive 4. The hypothesis persists that infections may trigger disease in susceptible individuals, but no specific pathogen has been definitively linked.
Clinical Implications
The pathophysiology explains key clinical features:
- Proximal muscle pain reflects local inflammatory cytokine production in muscle interstitium
- Rapid glucocorticoid response occurs because GCs suppress both systemic and local cytokine production
- Association with giant cell arteritis reflects shared immunopathologic mechanisms
- Age restriction reflects requirement for age-related immune alterations
Common pitfall: Assuming symptoms arise purely from joint inflammation leads to underappreciation of the muscle-based inflammatory process that directly causes patient symptoms 5.